Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients

Yunping Qiu, Bingsen Zhou, Mingming Su, Sarah Baxter, Xiaojiao Zheng, Xueqing Zhao, Yun Yen, Wei Jia

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Breast cancer accounts for the largest number of newly diagnosed cases in female cancer patients. Although mammography is a powerful screening tool, about 20% of breast cancer cases cannot be detected by this method. New diagnostic biomarkers for breast cancer are necessary. Here, we used a mass spectrometry-based quantitative metabolomics method to analyze plasma samples from 55 breast cancer patients and 25 healthy controls. A number of 30 patients and 20 age-matched healthy controls were used as a training dataset to establish a diagnostic model and to identify potential biomarkers. The remaining samples were used as a validation dataset to evaluate the predictive accuracy for the established model. Distinct separation was obtained from an orthogonal partial least squares-discriminant analysis (OPLS-DA) model with good prediction accuracy. Based on this analysis, 39 differentiating metabolites were identified, including significantly lower levels of lysophosphatidylcholines and higher levels of sphingomyelins in the plasma samples obtained from breast cancer patients compared with healthy controls. Using logical regression, a diagnostic equation based on three metabolites (lysoPC a C16:0, PC ae C42:5 and PC aa C34:2) successfully differentiated breast cancer patients from healthy controls, with a sensitivity of 98.1% and a specificity of 96.0%.

Original languageEnglish (US)
Pages (from-to)8047-8061
Number of pages15
JournalInternational Journal of Molecular Sciences
Volume14
Issue number4
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Metabolomics
breast
Lipids
Mass spectrometry
lipids
Mass Spectrometry
mass spectroscopy
cancer
Breast Neoplasms
Biomarkers
Metabolites
profiles
Plasmas
metabolites
biomarkers
Lysophosphatidylcholines
Mammography
Sphingomyelins
Discriminant analysis
Screening

Keywords

  • Breast cancer
  • Lipids
  • Metabolomics/metabonomics
  • Plasma

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Spectroscopy
  • Inorganic Chemistry
  • Medicine(all)

Cite this

Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. / Qiu, Yunping; Zhou, Bingsen; Su, Mingming; Baxter, Sarah; Zheng, Xiaojiao; Zhao, Xueqing; Yen, Yun; Jia, Wei.

In: International Journal of Molecular Sciences, Vol. 14, No. 4, 2013, p. 8047-8061.

Research output: Contribution to journalArticle

Qiu, Yunping ; Zhou, Bingsen ; Su, Mingming ; Baxter, Sarah ; Zheng, Xiaojiao ; Zhao, Xueqing ; Yen, Yun ; Jia, Wei. / Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. In: International Journal of Molecular Sciences. 2013 ; Vol. 14, No. 4. pp. 8047-8061.
@article{298f865cebdc4200ac546c87ebba1626,
title = "Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients",
abstract = "Breast cancer accounts for the largest number of newly diagnosed cases in female cancer patients. Although mammography is a powerful screening tool, about 20{\%} of breast cancer cases cannot be detected by this method. New diagnostic biomarkers for breast cancer are necessary. Here, we used a mass spectrometry-based quantitative metabolomics method to analyze plasma samples from 55 breast cancer patients and 25 healthy controls. A number of 30 patients and 20 age-matched healthy controls were used as a training dataset to establish a diagnostic model and to identify potential biomarkers. The remaining samples were used as a validation dataset to evaluate the predictive accuracy for the established model. Distinct separation was obtained from an orthogonal partial least squares-discriminant analysis (OPLS-DA) model with good prediction accuracy. Based on this analysis, 39 differentiating metabolites were identified, including significantly lower levels of lysophosphatidylcholines and higher levels of sphingomyelins in the plasma samples obtained from breast cancer patients compared with healthy controls. Using logical regression, a diagnostic equation based on three metabolites (lysoPC a C16:0, PC ae C42:5 and PC aa C34:2) successfully differentiated breast cancer patients from healthy controls, with a sensitivity of 98.1{\%} and a specificity of 96.0{\%}.",
keywords = "Breast cancer, Lipids, Metabolomics/metabonomics, Plasma",
author = "Yunping Qiu and Bingsen Zhou and Mingming Su and Sarah Baxter and Xiaojiao Zheng and Xueqing Zhao and Yun Yen and Wei Jia",
year = "2013",
doi = "10.3390/ijms14048047",
language = "English (US)",
volume = "14",
pages = "8047--8061",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients

AU - Qiu, Yunping

AU - Zhou, Bingsen

AU - Su, Mingming

AU - Baxter, Sarah

AU - Zheng, Xiaojiao

AU - Zhao, Xueqing

AU - Yen, Yun

AU - Jia, Wei

PY - 2013

Y1 - 2013

N2 - Breast cancer accounts for the largest number of newly diagnosed cases in female cancer patients. Although mammography is a powerful screening tool, about 20% of breast cancer cases cannot be detected by this method. New diagnostic biomarkers for breast cancer are necessary. Here, we used a mass spectrometry-based quantitative metabolomics method to analyze plasma samples from 55 breast cancer patients and 25 healthy controls. A number of 30 patients and 20 age-matched healthy controls were used as a training dataset to establish a diagnostic model and to identify potential biomarkers. The remaining samples were used as a validation dataset to evaluate the predictive accuracy for the established model. Distinct separation was obtained from an orthogonal partial least squares-discriminant analysis (OPLS-DA) model with good prediction accuracy. Based on this analysis, 39 differentiating metabolites were identified, including significantly lower levels of lysophosphatidylcholines and higher levels of sphingomyelins in the plasma samples obtained from breast cancer patients compared with healthy controls. Using logical regression, a diagnostic equation based on three metabolites (lysoPC a C16:0, PC ae C42:5 and PC aa C34:2) successfully differentiated breast cancer patients from healthy controls, with a sensitivity of 98.1% and a specificity of 96.0%.

AB - Breast cancer accounts for the largest number of newly diagnosed cases in female cancer patients. Although mammography is a powerful screening tool, about 20% of breast cancer cases cannot be detected by this method. New diagnostic biomarkers for breast cancer are necessary. Here, we used a mass spectrometry-based quantitative metabolomics method to analyze plasma samples from 55 breast cancer patients and 25 healthy controls. A number of 30 patients and 20 age-matched healthy controls were used as a training dataset to establish a diagnostic model and to identify potential biomarkers. The remaining samples were used as a validation dataset to evaluate the predictive accuracy for the established model. Distinct separation was obtained from an orthogonal partial least squares-discriminant analysis (OPLS-DA) model with good prediction accuracy. Based on this analysis, 39 differentiating metabolites were identified, including significantly lower levels of lysophosphatidylcholines and higher levels of sphingomyelins in the plasma samples obtained from breast cancer patients compared with healthy controls. Using logical regression, a diagnostic equation based on three metabolites (lysoPC a C16:0, PC ae C42:5 and PC aa C34:2) successfully differentiated breast cancer patients from healthy controls, with a sensitivity of 98.1% and a specificity of 96.0%.

KW - Breast cancer

KW - Lipids

KW - Metabolomics/metabonomics

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=84877015540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877015540&partnerID=8YFLogxK

U2 - 10.3390/ijms14048047

DO - 10.3390/ijms14048047

M3 - Article

C2 - 23584023

AN - SCOPUS:84877015540

VL - 14

SP - 8047

EP - 8061

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 4

ER -